Vitamin K2 supplementation research for pregnant Chinese women and bone health outcomes
Clinical study examining the relationship between Vitamin K2 levels and bone density in pregnant Chinese women. The research investigates how K2 supplementation may support bone metabolism during pregnancy and lactation, addressing gaps in understanding maternal-fetal bone health and identifying high-risk groups for deficiency.
Overview
This research initiative addresses a critical gap in understanding the role of Vitamin K2 in bone metabolism among pregnant Chinese women. While previous studies have established a link between Vitamin K and bone mineralization in elderly populations, limited research has examined this relationship during pregnancy, when maternal bone density may decrease due to fetal skeletal development. The study aims to provide evidence-based guidance for Vitamin K2 supplementation recommendations during pregnancy and lactation.
The research will enroll 600 pregnant women in mid-to-late pregnancy and measure multiple health parameters including serum Vitamin K2 concentration, bone metabolism indicators, hematological and liver function markers, lipid profiles, and coagulation function. By integrating bone density measurements with gut microbiota analysis and pregnancy outcome tracking, the study seeks to establish actionable insights for maternal nutrition strategies.
Technical specifications
Study design and methodology:
- Participant cohort of 600 pregnant women aged 18-35 years with gestational age exceeding 14 weeks
- Inclusion criteria requiring no recent Vitamin K2 supplement consumption or high-K2 food intake within the past two months
- Bone density measurement to assess skeletal health status
- Vitamin K2 level assessment via serum concentration analysis
- Gut microbiota analysis to evaluate endogenous production potential
- Health and pregnancy outcome tracking throughout the study period
Observation indicators include:
- Serum Vitamin K2 concentration
- Bone metabolism-related biomarkers
- Hematological and liver function indicators
- Lipid profile measurements
- Coagulation function testing
Risk factors being investigated:
- Antenatal corticosteroid use
- Small for gestational age (SGA) births
- Cesarean section delivery
- Maternal gestational diabetes
- Premature rupture of membranes (PROM)
Technology readiness level
This research builds on a published August 2023 study in Saudi Med J by Liu and colleagues from Guangdong Medical University Affiliated Hospital, which examined 200 newborns and found that 33% had low serum Vitamin K2 levels. That study identified that newborns whose mothers used corticosteroids antenatally were nearly five times more likely to develop Vitamin K2 deficiency. The current expanded study with 600 participants represents an advanced validation phase that will provide more comprehensive data on the role of Vitamin K2 supplementation during pregnancy. Results will inform clinical recommendations for high-risk pregnant women and newborn supplementation protocols.
About Sungen Bioscience Co., LTD.
Sungen Bioscience Co., Ltd. (SungenBio) is an innovation-driven biotechnology firm specializing in the research, development, and industrial-scale fermentation of bioactive ingredients, including nattokinase, Vitamin K2 (MK-7), and gamma-polyglutamic acid (γ-PGA). Operating from its specialized biotechnology park in China, the company utilizes advanced fermentation and multi-stage membrane separation technologies to produce high-purity, standardized substances for the food, pharmaceutical, and nutritional supplement industries. Its proprietary production processes, often patent-protected, prioritize natural fermentation without the use of chemical solvents or preservatives, resulting in high-activity, clean-label ingredients marketed under brands such as ESSEK2 and EsseZyme.
The company serves as a critical supplier and solution provider for global partners seeking high-quality cardiovascular health and bone-support ingredients. By integrating independent R&D with academic cooperation, SungenBio maintains rigorous GMP-standard quality management, supporting its efforts to meet international safety and regulatory standards, including European Novel Food approvals. Beyond ingredient manufacturing, the firm invests in clinical research to validate the efficacy of its products, addressing health use cases such as cardiovascular function, osteoporosis prevention, and blood sugar management. This commitment to scientific backing and scalable, eco-friendly manufacturing positions SungenBio as an established player in the global bioactive ingredient market.
delivered to your inbox.